Key Points
- Takeda insider Awny Samaan Botros Farajallah sold 14,006 shares at an average price of $17.10, generating $239,502.60. The sale reduced the insider’s holdings by 10.76% and was made to cover tax withholding on vested equity awards.
- Takeda’s shares opened at $17.41, with a market capitalization of approximately $55.77 billion and a 12-month range of $12.99 to $18.90. Its latest quarter included $6.90 billion in revenue and $0.56 in EPS, while analysts expect about $3.01 in full-year EPS.
- Analyst sentiment is mixed, with two Buy ratings, one Hold and one Sell, resulting in a consensus Hold rating. Several institutional investors increased their positions, although institutional ownership remains relatively low at 9.17%.
Takeda Pharmaceutical Co. (NYSE:TAK - Get Free Report) insider Awny Samaan Botros Farajallah sold 14,006 shares of the firm's stock in a transaction that occurred on Monday, August 10th. The shares were sold at an average price of $17.10, for a total value of $239,502.60. Following the completion of the transaction, the insider owned 116,177 shares of the company's stock, valued at approximately $1,986,626.70. The trade was a 10.76% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. The sale was made to cover tax withholding obligations related to the vesting of equity awards.
Takeda Pharmaceutical Price Performance
Shares of TAK stock opened at $17.41 on Friday. The business's fifty day moving average is $16.53 and its 200 day moving average is $17.14. The company has a quick ratio of 0.62, a current ratio of 1.14 and a debt-to-equity ratio of 0.58. The stock has a market cap of $55.77 billion, a price-to-earnings ratio of 51.19 and a beta of -0.08. Takeda Pharmaceutical Co. has a twelve month low of $12.99 and a twelve month high of $18.90.
Takeda Pharmaceutical (NYSE:TAK - Get Free Report) last announced its quarterly earnings data on Tuesday, March 31st. The company reported $0.56 EPS for the quarter. Takeda Pharmaceutical had a return on equity of 10.95% and a net margin of 3.80%.The business had revenue of $6.90 billion during the quarter. Research analysts expect that Takeda Pharmaceutical Co. will post 3.01 EPS for the current fiscal year.
Wall Street Analyst Weigh In
A number of equities analysts have weighed in on the stock. Weiss Ratings downgraded shares of Takeda Pharmaceutical from a "hold (c-)" rating to a "sell (d+)" rating in a research note on Thursday, July 30th. Wall Street Zen raised Takeda Pharmaceutical from a "hold" rating to a "buy" rating in a research report on Saturday, July 18th. Finally, Zacks Research upgraded Takeda Pharmaceutical from a "strong sell" rating to a "hold" rating in a research note on Tuesday, August 4th. Two analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has given a Sell rating to the company. According to MarketBeat.com, Takeda Pharmaceutical presently has an average rating of "Hold".
Check Out Our Latest Stock Analysis on Takeda Pharmaceutical
Hedge Funds Weigh In On Takeda Pharmaceutical
Hedge funds have recently bought and sold shares of the company. Capital Research Global Investors increased its stake in Takeda Pharmaceutical by 0.6% during the 4th quarter. Capital Research Global Investors now owns 13,486,772 shares of the company's stock valued at $210,259,000 after purchasing an additional 82,643 shares in the last quarter. UBS Group AG grew its holdings in shares of Takeda Pharmaceutical by 46.4% during the third quarter. UBS Group AG now owns 5,893,969 shares of the company's stock valued at $86,288,000 after buying an additional 1,869,323 shares during the last quarter. Arrowstreet Capital Limited Partnership raised its holdings in Takeda Pharmaceutical by 100.9% in the 4th quarter. Arrowstreet Capital Limited Partnership now owns 5,682,847 shares of the company's stock worth $88,596,000 after acquiring an additional 2,854,069 shares during the last quarter. Goldman Sachs Group Inc. raised its holdings in Takeda Pharmaceutical by 15.0% in the 1st quarter. Goldman Sachs Group Inc. now owns 5,320,793 shares of the company's stock worth $79,120,000 after acquiring an additional 692,404 shares during the last quarter. Finally, Renaissance Technologies LLC lifted its position in Takeda Pharmaceutical by 14.2% in the 1st quarter. Renaissance Technologies LLC now owns 2,989,100 shares of the company's stock valued at $55,358,000 after acquiring an additional 370,800 shares in the last quarter. Institutional investors own 9.17% of the company's stock.
Key Stories Impacting Takeda Pharmaceutical
Here are the key news stories impacting Takeda Pharmaceutical this week:
- Positive Sentiment: The tax-related nature of the transactions reduces their significance as a signal of deteriorating management confidence. Insiders continued to retain substantial positions after selling, including CEO Julie So-Young Kim, who retained 391,489 shares, and Andrew Stewart Plump, who retained 766,569 shares. Takeda insider sales report
- Neutral Sentiment: Analyst views remain mixed, with two Buy ratings, one Hold and one Sell, producing a consensus rating of “Hold.” Institutional ownership is relatively limited at 9.17%, although several funds recently increased their positions. Takeda stock analysis
- Neutral Sentiment: Takeda’s latest reported quarter included $0.56 in EPS and $6.90 billion in revenue. Analysts expect approximately $3.01 in earnings per share for the current year, providing a fundamental backdrop for the stock as it trades near its 12-month high. Takeda financial data
- Negative Sentiment: Multiple insiders sold a combined 444,100 shares for approximately $7.59 million at an average price of $17.10. The sellers included CEO Julie So-Young Kim, General Counsel Natalie Anne Marie Furney, Andrew Stewart Plump and other executives; individual ownership reductions ranged from 5.9% to 18.5%. The volume and seniority of the sellers may weigh on sentiment, even though the sales were made for tax purposes. SEC insider filing
About Takeda Pharmaceutical
(
Get Free Report)
Takeda Pharmaceutical Company Limited (NYSE: TAK) is a Tokyo-based, multinational biopharmaceutical company with roots dating back to 1781. The company researches, develops, manufactures and commercializes pharmaceutical and biopharmaceutical products for patients worldwide. Takeda is publicly listed and operates as a fully integrated R&D-driven healthcare company focused on delivering specialty medicines and therapies across a range of therapeutic areas.
Takeda's main business activities encompass discovery and development of prescription medicines, clinical development and regulatory affairs, manufacturing of small molecules and biologics, and global commercial operations.
Featured Stories
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
